Moderna Finance Chief Steps Down After Two Years—But Lands Deal For $42 Million Stock OptionsForbes • 04/11/22
Moderna's Lot Recall Is a Blot Despite Its Recent 2nd Covid-19 Booster ApprovalInvestorPlace • 04/11/22
Moderna begins dosing participants in a Phase 1/2 trial for its flu vaccine candidatesMarket Watch • 04/11/22
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine CandidatesAccesswire • 04/11/22